Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy.

Barkal AA, Weiskopf K, Kao KS, Gordon SR, Rosental B, Yiu YY, George BM, Markovic M, Ring NG, Tsai JM, McKenna KM, Ho PY, Cheng RZ, Chen JY, Barkal LJ, Ring AM, Weissman IL, Maute RL.

Nat Immunol. 2018 Jan;19(1):76-84. doi: 10.1038/s41590-017-0004-z. Epub 2017 Nov 27.

2.

Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity.

Ring NG, Herndler-Brandstetter D, Weiskopf K, Shan L, Volkmer JP, George BM, Lietzenmayer M, McKenna KM, Naik TJ, McCarty A, Zheng Y, Ring AM, Flavell RA, Weissman IL.

Proc Natl Acad Sci U S A. 2017 Dec 5;114(49):E10578-E10585. doi: 10.1073/pnas.1710877114. Epub 2017 Nov 20.

3.

Delivery of monocyte lineage cells in a biomimetic scaffold enhances tissue repair.

Hu MS, Walmsley GG, Barnes LA, Weiskopf K, Rennert RC, Duscher D, Januszyk M, Maan ZN, Hong WX, Cheung AT, Leavitt T, Marshall CD, Ransom RC, Malhotra S, Moore AL, Rajadas J, Lorenz HP, Weissman IL, Gurtner GC, Longaker MT.

JCI Insight. 2017 Oct 5;2(19). pii: 96260. doi: 10.1172/jci.insight.96260. [Epub ahead of print]

4.

Cancer immunotherapy targeting the CD47/SIRPα axis.

Weiskopf K.

Eur J Cancer. 2017 May;76:100-109. doi: 10.1016/j.ejca.2017.02.013. Epub 2017 Mar 10. Review.

PMID:
28286286
5.

Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20.

Weiskopf K, Anderson KL, Ito D, Schnorr PJ, Tomiyasu H, Ring AM, Bloink K, Efe J, Rue S, Lowery D, Barkal A, Prohaska S, McKenna KM, Cornax I, O'Brien TD, O'Sullivan MG, Weissman IL, Modiano JF.

Cancer Immunol Res. 2016 Dec;4(12):1072-1087. Epub 2016 Nov 14.

6.

Myeloid Cell Origins, Differentiation, and Clinical Implications.

Weiskopf K, Schnorr PJ, Pang WW, Chao MP, Chhabra A, Seita J, Feng M, Weissman IL.

Microbiol Spectr. 2016 Oct;4(5). doi: 10.1128/microbiolspec.MCHD-0031-2016. Review.

7.

Acute, Unilateral Breast Toxicity From Gemcitabine in the Setting of Thoracic Inlet Obstruction.

Weiskopf K, Creighton D, Lew T, Caswell JL, Ouyang D, Shah AT, Hofmann LV, Neal JW, Telli ML.

J Oncol Pract. 2016 Aug;12(8):763-4. doi: 10.1200/JOP.2016.014241. No abstract available.

8.

Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy.

Chhabra A, Ring AM, Weiskopf K, Schnorr PJ, Gordon S, Le AC, Kwon HS, Ring NG, Volkmer J, Ho PY, Tseng S, Weissman IL, Shizuru JA.

Sci Transl Med. 2016 Aug 10;8(351):351ra105. doi: 10.1126/scitranslmed.aae0501.

PMID:
27510901
9.

Antibody Therapy Targeting CD47 and CD271 Effectively Suppresses Melanoma Metastasis in Patient-Derived Xenografts.

Ngo M, Han A, Lakatos A, Sahoo D, Hachey SJ, Weiskopf K, Beck AH, Weissman IL, Boiko AD.

Cell Rep. 2016 Aug 9;16(6):1701-1716. doi: 10.1016/j.celrep.2016.07.004. Epub 2016 Jul 28.

10.

Salmonella Infection Enhances Erythropoietin Production by the Kidney and Liver, Which Correlates with Elevated Bacterial Burdens.

Li LX, Benoun JM, Weiskopf K, Garcia KC, McSorley SJ.

Infect Immun. 2016 Sep 19;84(10):2833-41. doi: 10.1128/IAI.00337-16. Print 2016 Oct.

11.

CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer.

Weiskopf K, Jahchan NS, Schnorr PJ, Cristea S, Ring AM, Maute RL, Volkmer AK, Volkmer JP, Liu J, Lim JS, Yang D, Seitz G, Nguyen T, Wu D, Jude K, Guerston H, Barkal A, Trapani F, George J, Poirier JT, Gardner EE, Miles LA, de Stanchina E, Lofgren SM, Vogel H, Winslow MM, Dive C, Thomas RK, Rudin CM, van de Rijn M, Majeti R, Garcia KC, Weissman IL, Sage J.

J Clin Invest. 2016 Jul 1;126(7):2610-20. doi: 10.1172/JCI81603. Epub 2016 Jun 13.

12.

SIRPα-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells.

Piccione EC, Juarez S, Tseng S, Liu J, Stafford M, Narayanan C, Wang L, Weiskopf K, Majeti R.

Clin Cancer Res. 2016 Oct 15;22(20):5109-5119. Epub 2016 Apr 28.

13.

Targeting lymphoma with precision using semisynthetic anti-idiotype peptibodies.

Torchia J, Weiskopf K, Levy R.

Proc Natl Acad Sci U S A. 2016 May 10;113(19):5376-81. doi: 10.1073/pnas.1603335113. Epub 2016 Apr 25.

14.

Identification of tumorigenic cells and therapeutic targets in pancreatic neuroendocrine tumors.

Krampitz GW, George BM, Willingham SB, Volkmer JP, Weiskopf K, Jahchan N, Newman AM, Sahoo D, Zemek AJ, Yanovsky RL, Nguyen JK, Schnorr PJ, Mazur PK, Sage J, Longacre TA, Visser BC, Poultsides GA, Norton JA, Weissman IL.

Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4464-9. doi: 10.1073/pnas.1600007113. Epub 2016 Mar 31. Erratum in: Proc Natl Acad Sci U S A. 2016 Sep 13;113(37):E5538.

15.

A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells.

Piccione EC, Juarez S, Liu J, Tseng S, Ryan CE, Narayanan C, Wang L, Weiskopf K, Majeti R.

MAbs. 2015;7(5):946-56. doi: 10.1080/19420862.2015.1062192.

16.

Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps.

Mitra S, Ring AM, Amarnath S, Spangler JB, Li P, Ju W, Fischer S, Oh J, Spolski R, Weiskopf K, Kohrt H, Foley JE, Rajagopalan S, Long EO, Fowler DH, Waldmann TA, Garcia KC, Leonard WJ.

Immunity. 2015 May 19;42(5):826-38. doi: 10.1016/j.immuni.2015.04.018.

17.

"Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis.

Ho CC, Guo N, Sockolosky JT, Ring AM, Weiskopf K, Özkan E, Mori Y, Weissman IL, Garcia KC.

J Biol Chem. 2015 May 15;290(20):12650-63. doi: 10.1074/jbc.M115.648220. Epub 2015 Apr 2.

18.

Macrophages are critical effectors of antibody therapies for cancer.

Weiskopf K, Weissman IL.

MAbs. 2015;7(2):303-10. doi: 10.1080/19420862.2015.1011450. Review.

19.

Q&A: Michael Bishop. Free thinker.

Bishop M, Weiskopf K.

Nature. 2014 Oct 16;514(7522):S9-10. doi: 10.1038/514S9a. No abstract available.

PMID:
25317596
20.

Targeting CD137 enhances the efficacy of cetuximab.

Kohrt HE, Colevas AD, Houot R, Weiskopf K, Goldstein MJ, Lund P, Mueller A, Sagiv-Barfi I, Marabelle A, Lira R, Troutner E, Richards L, Rajapaska A, Hebb J, Chester C, Waller E, Ostashko A, Weng WK, Chen L, Czerwinski D, Fu YX, Sunwoo J, Levy R.

J Clin Invest. 2014 Jun;124(6):2668-82. doi: 10.1172/JCI73014. Epub 2014 May 16.

21.

Improving macrophage responses to therapeutic antibodies by molecular engineering of SIRPα variants.

Weiskopf K, Ring AM, Schnorr PJ, Volkmer JP, Volkmer AK, Weissman IL, Garcia KC.

Oncoimmunology. 2013 Sep 1;2(9):e25773. Epub 2013 Jul 29.

22.

Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors.

Edris B, Willingham S, Weiskopf K, Volkmer AK, Volkmer JP, Mühlenberg T, Weissman IL, van de Rijn M.

Oncoimmunology. 2013 Jun 1;2(6):e24452. Epub 2013 May 14.

23.

Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies.

Weiskopf K, Ring AM, Ho CC, Volkmer JP, Levin AM, Volkmer AK, Ozkan E, Fernhoff NB, van de Rijn M, Weissman IL, Garcia KC.

Science. 2013 Jul 5;341(6141):88-91. doi: 10.1126/science.1238856. Epub 2013 May 30.

24.

Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response.

Tseng D, Volkmer JP, Willingham SB, Contreras-Trujillo H, Fathman JW, Fernhoff NB, Seita J, Inlay MA, Weiskopf K, Miyanishi M, Weissman IL.

Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):11103-8. doi: 10.1073/pnas.1305569110. Epub 2013 May 20.

25.

Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth.

Edris B, Willingham SB, Weiskopf K, Volkmer AK, Volkmer JP, Mühlenberg T, Montgomery KD, Contreras-Trujillo H, Czechowicz A, Fletcher JA, West RB, Weissman IL, van de Rijn M.

Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3501-6. doi: 10.1073/pnas.1222893110. Epub 2013 Feb 4.

26.

Flipping the script on macrophages in leiomyosarcoma.

Edris B, Weiskopf K, Weissman IL, van de Rijn M.

Oncoimmunology. 2012 Oct 1;1(7):1202-1204.

27.

A nonpeptidic cathepsin S activity-based probe for noninvasive optical imaging of tumor-associated macrophages.

Verdoes M, Edgington LE, Scheeren FA, Leyva M, Blum G, Weiskopf K, Bachmann MH, Ellman JA, Bogyo M.

Chem Biol. 2012 May 25;19(5):619-28. doi: 10.1016/j.chembiol.2012.03.012.

28.

Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma.

Edris B, Weiskopf K, Volkmer AK, Volkmer JP, Willingham SB, Contreras-Trujillo H, Liu J, Majeti R, West RB, Fletcher JA, Beck AH, Weissman IL, van de Rijn M.

Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6656-61. doi: 10.1073/pnas.1121629109. Epub 2012 Mar 26.

29.

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.

Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD, Lovelace P, Scheeren FA, Chao MP, Weiskopf K, Tang C, Volkmer AK, Naik TJ, Storm TA, Mosley AR, Edris B, Schmid SM, Sun CK, Chua MS, Murillo O, Rajendran P, Cha AC, Chin RK, Kim D, Adorno M, Raveh T, Tseng D, Jaiswal S, Enger PØ, Steinberg GK, Li G, So SK, Majeti R, Harsh GR, van de Rijn M, Teng NN, Sunwoo JB, Alizadeh AA, Clarke MF, Weissman IL.

Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6662-7. doi: 10.1073/pnas.1121623109. Epub 2012 Mar 26.

30.

Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer.

Kohrt HE, Houot R, Weiskopf K, Goldstein MJ, Scheeren F, Czerwinski D, Colevas AD, Weng WK, Clarke MF, Carlson RW, Stockdale FE, Mollick JA, Chen L, Levy R.

J Clin Invest. 2012 Mar;122(3):1066-75. doi: 10.1172/JCI61226. Epub 2012 Feb 13.

31.

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.

Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, Müller A, Pachynski R, Czerwinski D, Coutre S, Chao MP, Chen L, Tedder TF, Levy R.

Blood. 2011 Feb 24;117(8):2423-32. doi: 10.1182/blood-2010-08-301945. Epub 2010 Dec 30.

32.

Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47.

Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J, Weiskopf K, Willingham SB, Raveh T, Park CY, Majeti R, Weissman IL.

Sci Transl Med. 2010 Dec 22;2(63):63ra94. doi: 10.1126/scitranslmed.3001375.

33.

Asterless is a scaffold for the onset of centriole assembly.

Dzhindzhev NS, Yu QD, Weiskopf K, Tzolovsky G, Cunha-Ferreira I, Riparbelli M, Rodrigues-Martins A, Bettencourt-Dias M, Callaini G, Glover DM.

Nature. 2010 Oct 7;467(7316):714-8. doi: 10.1038/nature09445. Epub 2010 Sep 19.

PMID:
20852615

Supplemental Content

Loading ...
Support Center